Ownership and insider activity for Lexeo Therapeutics, Inc. Common Stock (LXEO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates.
Price
| Price | $4.16 |
| Market Cap | $327M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.4M | $135.9M | $77.3M | $121.5M | $35.0M | $63.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | $86.5M | $118.8M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $29.4M | $136.7M | $80.0M | $124.3M | $126.1M | $188.4M |
| Property, Plant & Equipment | 0 | $174000 | $13.8M | $12.3M | $10.6M | $8.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $29.4M | $136.9M | $97.1M | $139.8M | $146.9M | $268.7M |
| Accounts Payable | $44319 | $3.1M | $2.7M | $3.8M | $6.4M | $4.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | $2.7M | 0 |
| Total Current Liabilities | $697722 | $7.4M | $14.3M | $17.2M | $22.8M | $16.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $34.9M | $192.5M | $210.0M | $26.3M | $30.1M | $22.0M |
| Retained Earnings | -$5.5M | -$56.2M | -$115.4M | -$181.8M | -$280.2M | -$380.1M |
| Total Equity | -$5.5M | -$55.6M | -$113.0M | $113.5M | $116.8M | $246.7M |
| Total Debt | 0 | 0 | $13.5M | $11.6M | $9.9M | $7.9M |
| Net Debt | -$29.4M | -$135.9M | -$63.9M | -$109.8M | -$111.6M | -$173.9M |
| Working Capital | $28.7M | $129.2M | $65.7M | $107.1M | $103.3M | $171.6M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 13.89 |
Profitability
| Return on Equity | -41.85% |
| Return on Invested Capital | -39.33% |
| Return on Assets | -34.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AMRN · CAPR · CTNM · DBVT · KYTX · LRMR · MREO
Explore sector: Healthcare · Biotechnology
More sections of LXEO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks